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We would like to thank Dr. Koza for raising some importantetters to the Editor
he association between C-reactive protein
evel and left ventricular diastolic functions in
atientswithﬁrst ST-segment elevationmyocar-
ial infarction treated by primary coronary
ntervention
eywords:
-reactive protein
yocardial infarction
eft ventricular diastolic function
ear Editor,
I read with interest the article entitled “Association between
-reactive protein level and echocardiography assessed left
entricular function in ﬁrst ST-segment elevation myocardial
nfarctionpatientswhounderwent primary coronary intervention”
y Shacham et al. [1] in a recent issue of the Journal of Cardiology.
he authors concluded that admission of C-reactive protein (CRP)
evels is associated with echocardiographic parameters of elevated
eft ventricular (LV) ﬁlling pressure in patients with ST-segment
levation myocardial infarction (STEMI) treated with primary per-
utaneous coronary intervention (PPCI). I have some comments
bout this study.
CRP is a classic acute-phase protein that rises with a dynamic
ange of 10,000-fold within 6h and peaks at 48h [2]. Also, any
tent implantation is followedby a rapid increase inpostprocedural
RP levels [3]. In the ﬁrst paragraph of methods and patients sec-
ion of the present study, the authors mentioned CRP levels were
btained immediately following PPCI, but in the following para-
raph theymentioned blood samples for CRPwere drawn in all 173
atientswithin6hof admission to theemergency room. I think, this
onfounding sentence needs to be clariﬁed.
Another important caveat is the measurement time of echocar-
iographic parameters of the patients. The dynamic rise in CRP
evels (6–48h) can be a confounding factor on the parameters of
V diastolic function in that measured time (6–72h).
Additionally, body mass index, metabolic syndrome, diabetes
ellitus, hypertension, oral contraceptive use, physical exercise,
oderate alcohol consumption, periodontal disease, dietary pat-
erns, and smoking cause signiﬁcant variation in CRP levels [4].
In humans, statin treatment reduces levels of CRP [4]
nd the current and previous American College of Cardiology
oundation/AmericanHeart Association guidelines [5] recommend
igh-dose statin treatment early after admission in all STEMI
atients with Class 1 indication. Therefore, I wonder why Shacham
t al. [1]didnot initiate statin therapy inall patients; inotherwords,
s this a selection bias?
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reIn conclusion, adding CRP to existing variables for identifying
the patients at increased risk for long-term LV remodeling cannot
meaningfully alter clinical management.
Sincerely.
Conﬂict of interest
None.
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[Letters to the Editor / Journa
As stated by Dr Koza, C-reactive protein (CRP) is an acute-
hase protein which starts rising within 6h of the acute event
nd peaks at 48h [2]. Indeed the CRP levels were measured in our
atients within a median of 6.1h following symptom onset. Stent
mplantation may also induce a rapid increase in postprocedural
RP levels [3]. In accordance with that, CRP was determined in all
atients immediately after cardiac catheterization, resulting in all
erum samples for CRP collected no longer than 6h after hospital
dmission, andwe believe that this proximity of CRPmeasurement
robably negated the effect of the angioplasty on CRP levels. Sim-
larly, as we measured only admission CRP levels, we believe that
t had no confounding effect on the parameters of left ventricular
iastolic functions assessed 6–72h following admission. Another
oint raisedwas the negative effect of statins on CRP levels, and the
ecent American College of Cardiology Foundation/American Heart
ssociation guidelines [4] recommending high-dose statin treat-
ent early after admission in all ST-elevationmyocardial infarction
atients as a Class I indication. Indeed in all study patients, treat-
ent with high-dose statins was started early after admission. As
ll patients were taken directly from the emergency room to the
atheterization laboratory, statin treatment was started follow-
ng primary percutaneous coronary intervention upon intensive
are unit admission. We concur that as peak CRP levels were not
ssessed throughout hospitalization the early anti-inﬂammatory
ffect of statins could not be determined.
Finally, as stated by Dr Koza various factors can be associated
ith signiﬁcant variation in CRP levels [5], however these con-
ounding factors can practically be found in any real-life population
here CRP was previously studied.
In conclusion, we would like to emphasize, as we have in therticle, that the mechanisms underlying the relation between CRP
nd diastolic dysfunction are not known. As CRP is known to be a
arker of adverseoutcome inmyocardial infarctionpatients, larger
linical trials are required to prove its effect.rdiology 64 (2014) 328–329 329
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